Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (ANCHOR)

This study has been completed.
Information provided by (Responsible Party):
Amarin Pharma Inc. Identifier:
First received: January 11, 2010
Last updated: November 5, 2013
Last verified: November 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 10, 2013